Timothy B. Johnson - Jul 12, 2022 Form 4 Insider Report for MARRONE BIO INNOVATIONS INC (MBII)

Role: VP (Field and Technical)
Signature: /s/ Linda V. Moore, as attorney in fact
Stock symbol: MBII
Transactions as of: Jul 12, 2022
Transactions value $: $0
Form type: 4
Date filed: 7/15/2022, 11:13 AM
Previous filing: Mar 18, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MBII	Common Stock	Award	$0	+102K	+92.7%	$0.00	212K	Jul 12, 2022	Direct	F1, F2, F3
transaction	MBII	Common Stock	Disposed to Issuer		-212K	-100%		0	Jul 12, 2022	Direct	F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MBII	Restricted Stock Units	Options Exercise	$0	-102K	-100%	$0.00^*	0	Jul 12, 2022	Common Stock	102K		Direct	F2, F5, F6
transaction	MBII	Stock Option (Right to Buy)	Disposed to Issuer		-155K	-100%		0	Jul 12, 2022	Common Stock	155K	$0.63	Direct	F7
transaction	MBII	Stock Option (Right to Buy)	Disposed to Issuer		-50K	-100%		0	Jul 12, 2022	Common Stock	50K	$1.23	Direct	F8
transaction	MBII	Stock Option (Right to Buy)	Disposed to Issuer		-200K	-100%		0	Jul 12, 2022	Common Stock	200K	$1.44	Direct	F9
transaction	MBII	Stock Option (Right to Buy)	Disposed to Issuer		-200K	-100%		0	Jul 12, 2022	Common Stock	200K	$1.65	Direct	F10
transaction	MBII	Stock Option (Right to Buy)	Disposed to Issuer		-6K	-100%		0	Jul 12, 2022	Common Stock	6K	$2.87	Direct	F11
transaction	MBII	Stock Option (Right to Buy)	Disposed to Issuer		-1.27K	-100%		0	Jul 12, 2022	Common Stock	1.27K	$12.00	Direct	F12
transaction	MBII	Stock Option (Right to Buy)	Disposed to Issuer		-33.3K	-100%		0	Jul 12, 2022	Common Stock	33.3K	$18.01	Direct	F13

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Timothy B. Johnson is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	Any unvested restricted stock units became vested and all restricted stock units were delivered to the Reporting Person, pursuant to the grant terms, immediately prior to the change of control transaction (the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 16, 2022, by and between Bioceres Crop Solutions Corp., BCS Merger Sub, Inc., and Issuer (the "Merger Agreement").
F2	The settlement of restricted stock units is being reported as one award; however, a number of awards of restricted stock units, as reported in prior Forms 4, are being settled. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, upon request, details of the awards previously granted and settled as set forth in this footnote to this Form 4.
F3	The number of securities reported also reflects the acquisition of a total of 5,051 shares of the issuer's common stock pursuant to the issuer's employee stock purchase plan.
F4	Disposed of pursuant to the Merger Agreement in exchange for 16,164 BIOX Ordinary Shares having a market value of $9.44 per share on the effective date of the Merger and 2,524 restricted stock units (each restricted stock unit represents a contingent right to receive one Ordinary Share of BIOX).
F5	Each restricted stock unit represented a contingent right to receive one share of Marrone Bio Innovations, Inc. common stock.
F6	Any unvested restricted stock units vested completely immediately prior to the Merger, and the underlying shares were delivered to the Reporting Person immediately prior to the Merger in accordance with the terms of the grants.
F7	This option, which provided for vesting in equal monthly installments over three years, beginning on March 7, 2022, was assumed by BIOX with respect to 66,935 shares and replaced with an option to purchase 5,890 Ordinary Shares of BIOX for $7.16 per share. The remainder of the option was cancelled in the Merger in exchange for 3,368 Ordinary Shares of BIOX having a market value of $9.44 per share on the effective date of the Merger.
F8	This option, which provided for vesting 1/3 of the total shares subject to the option on the first anniversary of the vesting commencement date of March 1, 2016, and with respect to 1/36 of the total shares subject to the option monthly thereafter for 24 months, was assumed by BIOX in the Merger and replaced with an option to purchase 4,400 Ordinary Shares of BIOX for $13.98 per share.
F9	This option, which provided for vesting in equal monthly installments over 48 months at the rate of 1/48th after the vesting commencement date of July 16, 2019, was assumed by BIOX in the Merger and replaced with an option to purchase 17,600 Ordinary Shares of BIOX for $16.36 per share.
F10	This option, which provided for vesting over a period of four years, with 1/4th of the shares subject to the option vesting twelve months after the vesting commencement date of May 3, 2018, and the remaining shares vesting in equal monthly installments over the remaining 36 months at the rate of 1/48th, was assumed by BIOX in the Merger and replaced with an option to purchase 17,600 Ordinary Shares of BIOX for $18.75 per share.
F11	This option, which provided for vesting with respect to 100% of the total shares subject to the option on December 31, 2015, was assumed by BIOX in the Merger and replaced with an option to purchase 528 Ordinary Shares of BIOX for $32.61 per share.
F12	This option, which provided for vesting with respect to 1/4th of the total shares subject to the option on the first anniversary of the vesting commencement date of August 2, 2013, and 1/48th of the total shares subject to the option monthly thereafter for 36 months, was assumed by BIOX in the Merger and replaced with an option to purchase 112 Ordinary Shares of BIOX for $136.36 per share.
F13	This option, which provided for vesting with respect to 1/4th of the total shares subject to the option on the first anniversary of the vesting commencement date of September 27, 2013, and with respect to 1/48th of the total shares subject to the option monthly thereafter for 36 months, was assumed by BIOX in the Merger and replaced with an option to purchase 2,933 Ordinary Shares of BIOX for $204.66 per share.